Search

Researchers found that a common cancer gene called PIK3CA also causes the condition venous malformation. Their discovery has already pointed the way to targeted therapies for this rare and painful condition that affects one in 10,000 people.

Meet MSK Research Scholar Moralba Dominguez Garcia, PhD: “I wanted to do something that creates knowledge — and that can help other people.”

Learn how HPV-related head and neck cancer can be treated with a sharply reduced radiation dose to prevent side effects, sometimes without surgery.

A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The updated PACIFIC trial data will be presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), by Andreas Rimner, MD, radiation oncologist, Memorial Sloan Kettering Cancer Center.

Sloan Kettering Institute scientists are using zebrafish to understand human skin cancer that attacks the hands and feet.

Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments.

A retrospective study by urologists at MSKCC and their colleagues, suggests that this practice needs to be re-evaluated. Researchers add that with advances in imaging, almost 70 percent of kidney cancer patients have their tumor detected at a very small size allowing surgeons to perform less radical surgery with superior results.

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus treatment with sunitinib (Sutent®) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) that were reported online today in the New England Journal of Medicine.